People Round-Up: Glenmark Recruits API Head From Mylan

Glenmark Pharmaceuticals has appointed Yasir Rawjee as CEO of its active pharmaceutical ingredient subsidiary Glenmark Life Sciences. He joins the Indian firm from Mylan, where he was most recently head of global API operations, having held positions of increasing responsibility in the firm’s API business during his career there. Rawjee has also served at GlaxoSmithKline and Matrix Laboratories, which was acquired by Mylan. Glenmark’s chairman and managing director, Glenn Saldanha, said the firm saw “significant growth potential in our API business given the increasing demand for good quality and sustained supply of APIs globally”, noting that “with this view, we housed our API business into a separate subsidiary which will be run independently.” Rawjee pledged to “contribute meaningfully in scaling up and shaping the next leg of growth for the API unit.”

Lannett’s chief financial officer, Martin Galvan, has announced plans to retire on 30 August 2019, following the submission of the firm’s Form 10-K annual report for its 2019 fiscal year. The company said it was “conducting a search for its next CFO, which includes internal and external candidates.” Galvan, 67, will serve as a consultant “as necessary” following his departure